Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Keyphrases

• Gemcitabine 100%
• Phase II Trial 100%
• First-line Chemotherapy 100%
• Malignant Mesothelioma 100%
• Investigator-initiated 100%
• Switch Maintenance 100%
• Supportive Care 80%
• Disease Progression 40%
• Care Groups 40%
• Progression-free Survival 30%
• Adverse Events 20%
• Netherlands 20%
• Hazard Ratio 20%
• Best Supportive Care 20%
• Radiotherapy 10%
• Dutch 10%
• Treatment-related 10%
• Exclusion Criteria 10%
• Anemia 10%
• Intention-to-treat 10%
• 4-cycle 10%
• Organ Function 10%
• Computed Tomography 10%
• Anticancer Agents 10%
• Maintenance Therapy 10%
• Trial Registries 10%
• Neutropenia 10%
• Abdomen 10%
• First-line Therapy 10%
• Pulmonary Function Test 10%
• Lost to Follow-up 10%
• Thorax 10%
• Cough 10%
• Dyspnea 10%
• Palliative Radiotherapy 10%
• WHO Performance Status 10%
• Disabling Conditions 10%
• Blinded Independent Central Review 10%
• Asthenia 10%
• Uncontrolled Infection 10%
• Pemetrexed 10%
• CNS Metastases 10%
• Patient Demand 10%
• Intercurrent Illness 10%
• Minimization Problem 10%
• Concomitant Use 10%
• One-visit 10%
• No Evidence of Disease 10%
• Severe Cardiac Dysfunction 10%

Medicine and Dentistry

• Supportive Care 100%
• Gemcitabine 100%
• First-Line Chemotherapy 100%
• Mesothelioma 100%
• Infection 40%
• Disease Exacerbation 40%
• Care Group 40%
• Progression Free Survival 30%
• Disease 20%
• Adverse Event 20%
• Hazard Ratio 20%
• Malignant Neoplasm 10%
• Radiation Therapy 10%
• Metastatic Carcinoma 10%
• Anemia 10%
• Intention-to-Treat Analysis 10%
• Neutropenia 10%
• Symptomatic Treatment 10%
• Maintenance Therapy 10%
• Anticarcinogen 10%
• Lung Function Test 10%
• Chest 10%
• Coughing 10%
• Dyspnea 10%
• Pemetrexed 10%
• Asthenia 10%